首页 > 市场调查报告书 > 医疗设备

医学影像诊断 CT/MRI/X光

市场调查报告书

商品编码

1345417

全球光学相干断层扫描市场 - 2023-2030

Global Optical Coherence Tomography Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球光学相干断层扫描市场于2022年达到15亿美元，预计到2030年将达到28亿美元，2023-2030年预测期间复合年增长率为8.7%。

光学相干断层扫描利用光对组织排列进行微米级、原位、实时的横截面成像。这是一种非侵入性成像程序，用于进行光学活检。它用于无法使用传统成像方法的场所。 OCT建立在光纤基础上，可以与导管、腹腔镜、内窥镜和手术探针等工具结合，方便对身体进行成像。

在玻璃体视网膜疾病治疗中，OCT 相对于检眼镜检查的一个显着优势是能够限制玻璃体、视网膜和视网膜外膜之间的三维关联。 OCT的应用范围包括各种眼部疾病的诊断，如黄斑裂孔、黄斑水肿、黄斑皱褶、青光眼、年龄相关性黄斑变性、中心性浆液性视网膜病变、玻璃体牵引、糖尿病视网膜病变等。目前，OCT还用于诊断其他疾病的检测和诊断，例如心血管疾病、非黑色素瘤皮肤癌、前列腺癌和年龄相关性黄斑疾病等。

光学相干断层扫描主要受到眼科疾病病例不断增加、市场发展不断增加（包括合併、收购和产品发布等）的推动。此外，人们日益努力地宣传眼科疾病，以及心血管疾病、非黑色素瘤皮肤癌、前列腺癌和年龄相关性黄斑疾病等其他慢性疾病病例的增加，也促进了全球眼科疾病市场的增长。预测期。

动力学

眼科疾病病例不断增加

早期检测和监测对于青光眼的诊断和治疗至关重要，青光眼是一种导致不可逆失明的晚期视神经病变。光学相干断层扫描 (OCT) 已发展成为一种常用的成像方式，有助于检测和监测结构性青光眼恶化。因此，糖尿病视网膜病变的高患病率预计将在预测期内推动全球市场的增长。例如，糖尿病视网膜病变涉及由于血液中的高血糖水平而对眼睛视网膜造成的损伤。这是一种复杂的糖尿病，影响着数百万 1 型和 2 型糖尿病患者。

此外，其他眼科疾病病例的增加预计也将促进预测期内全球市场的增长。例如，根据世界卫生组织 2023 的数据，全球至少有 22 亿人存在近视力或远视力障碍，其中约 10 亿人的视力障碍本来可以避免或尚未得到处理。在国际范围内，视力障碍和失明的主要原因是屈光障碍和白内障。

在这10 亿人中，导致远视力障碍或失明的主要疾病包括影响超过9400 万人的白内障、影响约8840 万人的屈光不正、影响超过800 万人的年龄相关性黄斑变性、影响约770万人的青光眼和糖尿病视网膜病变病例超过 390 万例。导致近视力损伤的主要疾病是老花眼，这是一种与年龄相关的疾病，约有 8.26 亿人受到影响。

市场开发数量不断增加

不断增加的市场发展，包括合併、合作、产品发布和收购等，正在推动预测期内的全球市场增长。例如，海德堡工程公司于 2021 年 11 月推出了 Spectralis 平台，该平台配备移位技术，可提高 OCTA 和 OCT 的生产率，并允许临床医生切换 OCT 扫描速度，以实现更好的个性化评估。 Spectralis 平台提供三种扫描速率：20 kHz、85 kHz 和 125 kHz。

此外，佳能新加坡公司于2021 年7 月推出了Xephilio OCT-S1，这是一种创新的宽视场扫源光学相干拓扑技术，能够在单次扫描中捕获高达23×20 毫米的高分辨率图像。此外，2021 年 6 月，Perimeter Medical Imaging AI, Inc. 与 Minnetronix Medical 进行了光学相干断层扫描 (OCT) 成像系统生产製造方法的技术转让。 2021 年 10 月，NIDEK 再次推出了 Retina Scan Duo 2，它集成了眼底相机和 OCT。 Retina Scan Duo 2 具有增强筛查和临床有效性的特性，还有助于增强临床工作流程。

光学相干断层扫描设备成本高

光学相干断层扫描设备的高成本预计将阻碍全球市场的增长，因为成本高，资本投资低的从业者无力购买新设备，而是使用翻新设备，从而减缓了市场增长。例如，蔡司的 PRIMUS 200 价格约为 19,999.00 美元，同一製造商的 OCT cirrus 5000 价格约为 15,999.00 美元，Topcon OCT 2000 和 DRI OCT Triton 的价格分别约为 7,500.00 美元和 12,900.00 美元。

光学相干断层扫描设备的成本根据所包含的功能而有所不同，具有高级功能的设备比具有基本功能的设备成本更高，例如Optovue 的iScan OCT 成本约为12,000.00 美元，因为它包含一些高级功能，可以简化操作，而ivue来自同一製造商的 OCT 价格约为 9,999.00 美元，具有基本功能。

眼科医生劳动力短缺

眼科医生劳动力的短缺预计将在预测期内减缓全球市场的增长。例如，根据英国皇家眼科医师学院的数据，NHS 眼科服务的大部分都面临着巨大的能力压力，超过四分之三(76%) 的团队没有足够数量的顾问来满足现有患者的需求，甚至更多超过一半 (52%) 的人发现在过去 12 个月内招聘顾问也同样具有挑战性。

此外，2023年1月，全英格兰有超过632,000名眼科患者等待检查，其中24,000名患者等待时间超过一年。与 12 个月前相比，大约 74% 的眼科单位还担心门诊积压对患者维护的影响，63% 的眼科单位评估可能需要一年多的时间才能缓解门诊积压。此外，劳动力缺乏 NHS 眼保健援助的情况预计将会减少，英国四分之一（26%）的眼科医生考虑在未来五年内退出劳动力队伍。

Overview

Global Optical Coherence Tomography Market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.8 billion by 2030, growing with a CAGR of 8.7% during the forecast period 2023-2030.

Optical coherence tomography utilizes light for the cross-sectional imaging of the tissue arrangement on the micron scale, in situ, and in real time. It is a non-invasive imaging procedure, which is employed to conduct optical biopsies. It is employed in sites where conventional imaging approaches cannot be utilized. OCT is established on fiber optics and can be combined with the tools, like catheters, laparoscopes, endoscopes, and surgical probes, which facilitate imaging of the body.

A significant benefit of OCT over the ophthalmoscopic investigation in vitreoretinal disorder management is the capacity to confine three-dimensional associations between the vitreous, retina, and extraretinal membranes. The applications of OCT enclose the diagnosis of various eye disorders such as the macular hole, macular edema, macular pucker, glaucoma, age-related macular degeneration, central serous retinopathy, vitreous traction, diabetic retinopathy, etc. Presently, OCT is also utilized for the detection and diagnosis of other additional disorders such as cardiovascular diseases, non-melanoma skin cancer, prostate cancer, and age-related macular disease, among other.

The Optical coherence tomography is primarily boosted by the growing cases of opthalmic disorders, increasing market developments including mergers, acquisitions, and product launches among others. Further, the increasing efforts to spread awareness about opthamic disorders and growing cases of other chronic disorders including cardiovascular disorders, non-melanoma skin cancer, prostate cancer, and age-related macular disease, among others are also contributing to the global market growth in the forecast period.

Dynamics

Increasing Cases of Ophthalmic Disorder

Early detection and monitoring are essential to the diagnosis and management of glaucoma, an advanced optic neuropathy that induces irreversible blindness. Optical coherence tomography (OCT) has evolved into a typically employed imaging modality that assists in the detection and monitoring of structural glaucomatous deterioration. Thus, the high prevalence of diabetic retinopathy is expected to boost the global market growth during the forecast period. For instance, the diabetic retinopathy concerns injury to the eye's retina owing to high blood sugar levels in the blood. It is an expected intricacy of diabetes, impacting millions of individuals with both type 1 and type 2 diabetes.

Further, the growing cases of other ophthalmic disorders are also expected to be contributing to the global market growth in the forecast period. For instance, according to the WHO 2023, globally, at least 2.2 billion individuals are with near or distant vision impairment, and out of these around 1 billion vision impairment could have been averted or is yet to be handled. The top reasons for vision impairment and blindness at a multinational level are refractive disorders and cataracts.

Among these 1 billion individuals, the primary disorders inducing distance eyesight impairment or blindness include cataracts affecting over 94 million individuals, refractive error impacting around 88.4 million people, age-related macular degeneration with over 8 million cases, glaucoma affecting about 7.7 million individuals, and the diabetic retinopathy with over 3.9 million cases. The major disorder inducing near eyesight impairment is presbyopia an age-associated disease with around 826 million individuals impacted.

Increasing Number of Market Developments

The increasing number of market developments including, mergers, collaboration, product launches, and takeovers, among others are boosting the global market growth in the forecast period. For instance, in November 2021, Heidelberg Engineering revealed the Spectralis platform, which is provided with shift technology, improves productivity in OCTA and OCT, and also allows clinicians to switch OCT scan pace for a better-personalized assessment. The Spectralis platform delivers three scan rates, 20 kHz, 85 kHz, and 125 kHz.

Moreover, in July 2021, Canon Singapore introduced the Xephilio OCT-S1, an innovative wide-field swept-source optical coherence topography competent for capturing high-resolution images of up to 23×20 mm in a single scan. Also, in June 2021, Perimeter Medical Imaging AI, Inc. conducted the technology transfer of its manufacturing methodology for the production of its optical coherence tomography (OCT) imaging systems with Minnetronix Medical. Again, in October 2021, NIDEK introduced the Retina Scan Duo 2, an integration of a fundus camera and OCT. The Retina Scan Duo 2 is provided with characteristics that enhance screening, and clinical effectiveness, and additionally helps enhance clinical workflow.

High Optical Coherence Tomography Device Cost

The high cost of the optical coherence tomography devices is expected to hamper the global market growth as due to the high cost the practitioners with low capital investments can not afford to buy a new device and instead of which use refurbished ones, slowing the market growth. For instance, the PRIMUS 200 from Zeiss costs around US$ 19,999.00, the OCT cirrus 5000 from the same manufacturer costs about US$ 15,999.00, Topcon OCT 2000 and DRI OCT Triton both from Topocon costs about US$ 7,500.00 and US$ 12,900.00 respectively.

The optical coherence tomography device cost varies based upon the features included the device with advanced features costs more compared to the one with basic features for example iScan OCT from Optovue costs around US$ 12,000.00 as it includes some advanced features which deliver simplified operations while the ivue OCT from the same manufacturer costs about US$ 9,999.00 having basic features.

Opthalmologists Workforce Shortage

The shortage of ophthalmologists workforce is expected to slow the global market growth during the forecast period. For instnace, according to the Royal College of Ophthalmologists, the extensive bulk of NHS ophthalmology services are encountering substantial capability stresses, with more than three-quarters (76%) of teams not including an adequate number of consultants to satisfy existing patient needs and more than a half (52%) discovering it is additionally challenging to recruit consultants over the previous 12 months.

Moreover, in January 2023, there were more than 632,000 patients on ophthalmology waiting checklists in England sole and 24,000 of which were waiting for more than a year. Around 74% of eye units are additionally concerned regarding the effect of outpatient backlogs on patient upkeep than they were 12 months back and 63% assess it might take over a year to alleviate their outpatient backlogs. Further, the workforce's lack of NHS eyecare assistance is expected to decline, with a quarter (26%) of ophthalmologists in the UK thinking to exit the workforce over the next five years.

Segment Analysis

The global optical coherence tomography market is segmented based on product type, volume scan, technology, application, end-user and region.

Cancer Application of OCT Expected to Dominate Market

The oncology application of the OCT is expected to dominate the global market owing to the increasing number of positive outcomes from investigations intended to assess the efficacy of OCT in cancer diagnosis. For instance, in an investigation, investigators corresponded the diagnostic precision of clinical and dermoscopic examination (CDE) with that of CDE integrated with OCT for detecting recurrent or residual BCC post topical therapy of superficial BCC. When utilized in integration with the clinical and dermoscopic study, optical coherence tomography remarkably enhanced the capability to notice recurrent or residual basal cell carcinomas post-topical treatment.

Moreover, in July 2023, a transnational group of investigators improved the procedure of optical coherence tomography (OCT) which carries importance for ophthalmology, dermatology, cardiology, and the early diagnosis of cancer. The work was instructed by the University of Adelaide, Technical University of Denmark (DTU), Aerospace Corp., and the University of St. Andrews.

Also, in August 2022, the Lancet Oncology presented ground-breaking conclusions on Michelson Diagnostics, the UK-based medical device corporation that uses multi-beam Optical Coherence Tomography ('OCT') technology, which can convert patient therapy and maintenance of basal cell carcinomas (BCC). It was inferred that OCT-guided diagnosis, when corresponding to a classic punch biopsy could decrease the number of consultations and invasive approaches by a huge 66%.

Geographical Penetration

Increasing Number of Ophthalmic Disorders Cases in North America

The increasing prevalence of ophthalmic disorders in North America is expected to boost regional market growth in the forecast period. For instance, in the United States independently, almost 12 million individuals aged 40 and overhead encountered eyesight impairment, with almost a million suffering from blindness. The CDC notifies that 17.2% of Americans above 40 years of age have a cataract in at least one eye accounting for around 20.5 million individuals. By 2028, above 30 million individuals are expected to suffer from cataracts. The CDC assesses that 4.1 million Americans are impacted with diabetic retinopathy, and almost 900,000 Americans are threatened with vision-damaging retinopathy.

With the growth in life expectancy, diabetes, and other chronic conditions, the cases of eye disorders are anticipated to increase twofold by the year 2050. Age-related macular degeneration (AMD) is the highly expected reason for irreversible eyesight loss in older adults (70 years and older), with an assessed 9 million Americans suffering from intermediate or progressive AMD. Moreover, in 2021, an assessed 9.6 million individuals in the United States, 26% of those having diabetes encountered eye disease, and almost 2 million suffered the most extreme form, "vision-threatening diabetic retinopathy" (VTDR).

Further, the increasing government initiatives to fight against the growing prevalence of eye disorders in the region also contribute to the regional market growth in the forecast period. For instance, in December 2022, congress declared its long-awaited Fiscal Year (FY) 2023 expenditure ruling, which retains a sum of $6.5 million for vision and eye health agendas at the Centers for Disease Control and Prevention (CDC).

In certain, the omnibus spending ruling would sponsor the Vision Health Initiative (VHI) at $2.5 million in FY2023, a $1 million growth over FY2022. The addition would support measures to revise national preponderance assessments on vision impairment and eye disorder. The CDC's Glaucoma project, which supports community-based agendas that unite high-risk patients to eye care, would persist to be sponsored at $4 million.

COVID-19 Impact Analysis

Presently, ophthalmic practice widely relies on optic coherence tomography (OCT) and optical coherence tomography angiography (OCT-A), which are objective, reliable, and repeatable structural difficulties for both earlier diagnosis and detection of the advancement of various ocular conditions. The missed clinic visits advanced dramatically during the COVID-19 pandemic, particularly among elderly and nonwhite patients. These findings reflect differences in eye care delivery during the pandemic and they indicate possibilities to target barriers to care, even during non-pandemic eras.

However, individuals responded in diverse patterns to COVID-19 conditions. While some individuals produced mild to extreme respiratory issues, others encounter no manifestations at all. Pink eye remained the most typical manifestation of COVID in the eyesight of children and adults. Thus, COVID-19 is estimated to hold intermediate impact over the global market growth in the forecast period.

Russia-Ukraine Impact

The Russia Ukraine conflict is expected to have a very little impact over the global market, since the foremost weeks of the attack, Eyes on Ukraine, a humanitarian effort directed by ophthalmologists from across the nation, has been raising funds and shipping medication and surgical supplies to Ukraine ophthalmologists, with multiple reports from hospitals and war crews close to the front that the cargoes are making a general distinction.

Obtaining reserves into the nation, however, has demanded invention and the forging of a trusted network of people, including European ophthalmologists and Polish and Ukrainian mountain defenses, to assure safe transportation of the goods via Poland to Western Ukraine. There, they are distributed by the Ukrainian Vitreoretinal Society to where they are needed considerable. The initiative is believed to be the most active and organized humanitarian help initiatives sustaining eye trauma in the Russian invasion of Ukraine.

By Product Type

Handheld
Tabletop
Doppler
Catheter Based
Others

By Volume Scan

Annular
Raster
Radial
Others

By Technology

Frequency Domain
Spatially Encoded Frequency Domain
Time Domain
Others

By Application

Ophthalmology
Cardiology
Dermatology
Oncology
Others

By End-User

Hospitals
Specialty Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In January 2023, Thorlabs acquired JML Optical, a US-based precision optics firm. The acquisition of JML Optical broadens Thorlabs' optical elements offerings. Cashing on JML's optic abilities and manufacturing & innovation presence in Rochester, New York allows Thorlabs to provide revolutionary innovations for the photonics market.
In February 2023, NIDEK launched AL-Scan M Optical Biometer and MV-1 Myopia Viewer software. The AL-Scan is crucial for assessing young children and provides smooth patient flow. The biometer measures axial length, which is believed to be an perfect parameter for evaluating myopia.
In October 2022, the European Association of Neurosurgical Societies and ZEISS Medical Technology formed a strategic cooperation (EANS). The business expects that through this association, it expects to be capable of assisting in the training and additional education of neurosurgical professionals, facilitating the exchange of knowledge between users and medical equipment manufacturers, and enhancing scientific progress in the domain of neurosurgery.

Competitive Landscape

The major global players in the market include: Thorlabs, Inc., ZEISS, Topcon Corporation, Leica Microsystems, NIDEK CO., LTD., Heidelberg Engineering Inc., Alcon Inc., Canon Medical Systems, USA., Visionix Ltd. , Abbott, Icare USA, Inc., and OPTOPOL Technology Sp among others.

Why Purchase the Report?

To visualize the global optical coherence tomography market segmentation based on product type, volume scan, technology, application, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of optical coherence tomography market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key product of all the major players.

The global optical coherence tomography market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Volume Scan
3.3. Snippet by Technology
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Cases of Ophthalmic Disorder
  - 4.1.1.2. Increasing Number of Market Developments
- 4.1.2. Restraints
  - 4.1.2.1. High Optical Coherence Tomography Device Cost
  - 4.1.2.2. Ophthalmologists Workforce Shortage
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. End-User Trend
5.7. SWOT Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Handheld*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Tabletop
- 7.2.4. Doppler
- 7.2.5. Catheter Based
- 7.2.6. Others

8. By Volume Scan

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 8.1.2. Market Attractiveness Index, By Volume Scan
8.2. Annular*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. Raster
- 8.2.4. Radial
- 8.2.5. Others

9. By Technology

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.1.2. Market Attractiveness Index, By Technology
9.2. Frequency Domain*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Spatially Encoded Frequency Domain
9.4. Time Domain
9.5. Others

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.1.2. Market Attractiveness Index, By Application
10.2. Ophthalmology*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cardiology
10.4. Dermatology
10.5. Oncology
10.6. Others

11. By End-User

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Clinics
11.4. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. UK
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. China
  - 12.5.8.2. India
  - 12.5.8.3. Japan
  - 12.5.8.4. Australia
  - 12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Thorlabs, Inc.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. ZEISS
14.3. Topcon Corporation
14.4. Leica Microsystems
14.5. NIDEK CO., LTD.
14.6. Heidelberg Engineering Inc.
14.7. Alcon Inc.
14.8. Canon Medical Systems, USA.
14.9. Visionix Ltd.
14.10. Abbott
14.11. Icare USA, Inc.
14.12. OPTOPOL Technology Sp

LIST NOT EXHAUSTIVE

15. Appendix

15.1. About Us and Services
15.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格